Diffuse Cutaneous Aphthosis After Combined Targeted Cancer Therapies and Responsive to Pentoxifylline

Cecilia A Larocca; Christopher J Fay; Jesse P Hirner; Jeffrey A Meyerhardt; James M Cleary; Anna K Dewan; Nicole R LeBoeuf

doi:10.1001/jamadermatol.2023.2649

Diffuse Cutaneous Aphthosis After Combined Targeted Cancer Therapies and Responsive to Pentoxifylline

JAMA Dermatol. 2023 Oct 1;159(10):1136-1139. doi: 10.1001/jamadermatol.2023.2649.

Authors

Cecilia A Larocca¹, Christopher J Fay¹, Jesse P Hirner², Jeffrey A Meyerhardt³, James M Cleary³, Anna K Dewan⁴, Nicole R LeBoeuf¹

Affiliations

¹ Center for Cutaneous Oncology, Department of Dermatology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts.
² Department of Dermatology, University of Missouri Health Care, Columbia.
³ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
⁴ Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee.

No abstract available

Plain language summary

This case series describes 3 patients who developed cutaneous aphthosis while taking an epidermal growth factor receptor inhibitor in combination with an MEK inhibitor.

Publication types

Letter

MeSH terms

Behcet Syndrome*
Humans
Neoplasms*
Pentoxifylline* / therapeutic use
Skin
Stomatitis, Aphthous*

Substances

Pentoxifylline